Article
Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Mar 2012
Wang Wei, Li Qi, Takeuchi Shinji, Yamada Tadaaki, Koizumi Hitomi, Nakamura Takahiro, Matsumoto Kunio, Mukaida Naofumi, Nishioka Yasuhiko, Sone Saburo, Nakagawa Takayuki, Uenaka Toshimitsu, Yano Seiji
Abstract excerpt
PURPOSE: Hepatocyte growth factor (HGF) induces resistance to reversible and irreversible epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) in EGFR mutant lung cancer cells by activating Met and the downstream phosphoinositide 3-kinase (PI3K)/Akt pathway. Moreover, continuous exposure to HGF accelerates the emergence of EGFR-TKI-resistant clones. We assayed whether a new Met kinase inhibitor,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.